<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="343323">
  <stage>Registered</stage>
  <submitdate>10/08/2011</submitdate>
  <approvaldate>17/08/2011</approvaldate>
  <actrnumber>ACTRN12611000876998</actrnumber>
  <trial_identification>
    <studytitle>To study the efficacy of strontium ranelate on the healing of surgically fixed diaphyseal tibial fractures and compare it to placebo</studytitle>
    <scientifictitle>Efficacy of Strontium Ranelate versus placebo on time to fracture healing of tibial fractures in adults</scientifictitle>
    <utrn>U1111-1123-2867</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Fracture healing</healthcondition>
    <conditioncode>
      <conditioncode1>Injuries and Accidents</conditioncode1>
      <conditioncode2>Fractures</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The purpose of this study is to study the efficacy of strontium ranelate in the dose of 2gm daily on the healing of surgically fixed diaphyseal tibial fractures and compare it to placebo. The subjects will receive strontium ranelate for a period of 3months commencing from the 1st day after fracture fixation. Strontium ranelate will be administered in an oral suspension form with yellow granules in a sachet to be mixed in 30ml water.</interventions>
    <comparator>Placebo, packed in identical sachets containing yellow placebo granules to be mixed in 30ml of water and to be administer in an oral suspension form.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>X rays will be done after fixation of fracture and then monthly for signs of fracture healing</outcome>
      <timepoint>immedate post operative and then monthly for total 3months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>All patients will be assessed at end of 3 months by independent observers  (Orthopedic Surgeon and a radiologist) for fracture healing
Standard criteria, clinical as well as radiological will be used to assess the patients.</outcome>
      <timepoint>End of 3months from date of surgery</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Levels of P1NP will be measured at time of enrollment and at 3 months and correlated with efficacy of fracture healing. This is a serum essay.</outcome>
      <timepoint>at time of enrollment and end of 3months from date of surgery</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>All adult patients between 18 and 60 years of age presenting with closed diaphysial tibial fractures, amenable to fixation with a Dynamic Compression Plate / Locking Compression Plate</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>All open fractures
Patients under 18 yrs or over 60 yrs
Metaphyseal /periarticular fractures
Patients with previous procedures in that limb
Fractures requiring bone grafting
Pregnant patients
Patients with renal impairment</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Patients meeting eligibility criteria will be randomized in a double blind fashion to receive either the study drug (strontium ranelate in a dose of 2gm daily in sachet form) or a placebo for 3 months.
Patients have been divided into Groups A and B to receive identical appearing pre-labeled and pre-packed medication boxes</concealment>
    <sequence>consecutive alternate sampling</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/08/2011</anticipatedstartdate>
    <actualstartdate>15/08/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate>24/04/2012</actualenddate>
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Pakistan</country>
      <state>Sindh</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Pharmevo (Pvt.) Ltd.</primarysponsorname>
    <primarysponsoraddress>402-Business Avenue
Block 6, P.E.C.H.S.
Shahrah-e-Faisal
Karachi. 75400</primarysponsoraddress>
    <primarysponsorcountry>Pakistan</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Pharmevo (Pvt.) Ltd.</fundingname>
      <fundingaddress>402-Business Avenue
Block 6, P.E.C.H.S.
Shahrah-e-Faisal
Karachi. 75400</fundingaddress>
      <fundingcountry>Pakistan</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>The Indus Hospital</sponsorname>
      <sponsoraddress>The Indus Hospital
Korangi Crossing
Korangi
Karachi. 75190</sponsoraddress>
      <sponsorcountry>Pakistan</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Strontium Ranelate is approved for treatment of osteoporosis. Its mode of action is thought to be a combination of anti resorptive and anabolic on bone. The bone forming ability has been documented in animal studies as well as in the increase in level of P1NP (A bone formation marker).
There are anecdotal reports that it enhances fracture healing in humans but very little prospective data is present. The purpose of this study is to study the efficacy of strontium ranelate in the dose of 2gm daily on the healing of surgically fixed diaphyseal tibial fractures and compare it to placebo.</summary>
    <trialwebsite />
    <publication>Presented Prospective Study in 27th International Pak-Orthocon (Findings Answers-Improving Lives) 21st Nov 2013 till 24th Nov 2013: Significance of P1NP Values In Assessment Of healing of surgically fixed Tibial Diaphyseal fractures treated with Strontium Ranelate V/S Placebo: A Randomised Double Blind Placebo control clinical Trial.
Poster Presentation in ICON (Indus Hospital Conference) 25 Jan 2014: Significance of P1NP Values In Assessment Of healing of surgically fixed Tibial Diaphyseal fractures treated with Strontium Ranelate V/S Placebo: A Randomised Double Blind Placebo control clinical Trial.
Free paper Significance Of P1NP Values In Assessment Of Fracture Healing Of Surgically Fixed Tibial Diapyseal Fractures Treated With Strontium Ranelate Vs Placebo; A Randomized Double Blind Controlled Trial----15th EFORT Congress in London from 4 - 6 June 2014.</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>IRD IRB</ethicname>
      <ethicaddress>Head Office
Suite 508, Ibrahim Trade Tower
Main Sharah-e-Faisal
Karachi, 75350</ethicaddress>
      <ethicapprovaldate>5/08/2011</ethicapprovaldate>
      <hrec>IRD_IRB_2011_7_005</hrec>
      <ethicsubmitdate />
      <ethiccountry>Pakistan</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Dr. Mansoor Ali Khan</name>
      <address>Department Of Orthopaedics
The Indus Hospital
Korangi Crossing
Korangi
Karachi. 75190</address>
      <phone>+92-300-8202537</phone>
      <fax>+92-21-35112718</fax>
      <email>makbonedoc65@gmail.com</email>
      <country>Pakistan</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Dr. M. Zeeshan Aslam</name>
      <address>Department Of Orthopaedics
The Indus Hospital
Korangi Crossing
Korangi
Karachi. 75190</address>
      <phone>+92-300-2322811</phone>
      <fax>+92-21-35112718</fax>
      <email>zeeshan_aslam_pk@yahoo.com</email>
      <country>Pakistan</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Dr. Syed Akmal Sultan</name>
      <address>Department Of Orthopaedics
The Indus Hospital
Korangi Crossing
Korangi
Karachi. 75190</address>
      <phone>+92-321-2380853</phone>
      <fax>+92-21-35112718</fax>
      <email>sakmalsultan@yahoo.com</email>
      <country>Pakistan</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Muhammad Zeeshan Aslam</name>
      <address>Department Of Orthopaedics The Indus Hospital Korangi Crossing Korangi Karachi. 75190</address>
      <phone>+92-300-2322811</phone>
      <fax>+92-21-35112718</fax>
      <email>zeeshan_aslam_pk@yahoo.com</email>
      <country>Pakistan</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>